Cryopyrin-associated Periodic Syndromes
📧 Sign up to get email alerts when something new happens for Cryopyrin-associated Periodic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load [Phase 1]
Phase 1 trial evaluating repeat PET/CT imaging with an amyloid-reactive peptide to measure changes in organ-specific amyloid load in people …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Circadian Rhythm Deregulation in Patients With CAPS [NA]
This clinical trial update indicates a study on circadian rhythm deregulation in patients with Cryopyrin-Associated Periodic Syndromes is cu…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Ilaris NIS in Korea
Novartis' canakinumab (Ilaris) is the subject of a Korea-based non-interventional study that is currently recruiting. The study covers hered…
-
EMA approval · 2025-10-13EMA Authorised: Ilaris (Canakinumab) — Novartis Europharm Limited
The EMA authorised Ilaris (canakinumab) for use in Cryopyrin-Associated Periodic Syndromes, juvenile idiopathic arthritis, and gout.
-
FDA label_change · 2021-03-18FDA Approved: ARCALYST — Supplemental Application (Kiniksa Pharmaceuticals (UK), Ltd.)
The FDA approved a supplemental application for ARCALYST (rilonacept) by Kiniksa Pharmaceuticals (UK), updating the drug's labeling to refle…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase [Phase 3]
Phase 3 study assessing 6-month efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes, includ…
-
CLINICAL_TRIALS trial_result · 2019-06-04Clinical Trial Update: A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS) [Phase 2]
Phase 2 clinical study investigating tranilast for Cryopyrin-Associated Periodic Syndromes (CAPS).
-
CLINICAL_TRIALS trial_result · 2017-01-04Clinical Trial Update: HL2351 CAPS Phase II Study [Phase 2]
Phase II study of HL2351 for Cryopyrin-associated periodic syndromes has been terminated.
-
FDA approval · 2016-09-23FDA Approved: ILARIS — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for ILARIS (canakinumab) submitted by Novartis Pharmaceuticals Corporation, resulting in an upda…
-
CLINICAL_TRIALS trial_result · 2016-08-03Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial assessing efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric patients with cryopyrin-associated periodic s…
-
CLINICAL_TRIALS trial_result · 2016-03-28Clinical Trial Update: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
This registry study assesses clinical outcomes and safety of canakinumab (Ilaris) in patients with cryopyrin-associated periodic syndromes (…
-
CLINICAL_TRIALS trial_result · 2015-08-18Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial evaluating ACZ885 (canakinumab) for efficacy, safety and tolerability in pediatric patients with Cryopyrin-associated periodic…
-
EMA withdrawal · 2012-10-30EMA Withdrawn: Rilonacept Regeneron (previously Arcalyst) (rilonacept) — Regeneron UK Limited
The EMA has withdrawn the marketing authorization for rilonacept (Regeneron UK Limited) previously branded Arcalyst, for Cryopyrin-Associate…
-
CLINICAL_TRIALS trial_result · 2011-05-27Clinical Trial Update: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 study evaluating ACZ885 (canakinumab) for efficacy and safety in cryopyrin-associated periodic syndromes, including familial cold au…
-
FDA approval · 2010-09-30FDA Approved: ARCALYST — Supplemental Application (Kiniksa Pharmaceuticals (UK), Ltd.)
The FDA approved a supplemental application for ARCALYST (rilonacept) by Kiniksa Pharmaceuticals (UK), Ltd., updating the existing approval.
-
CLINICAL_TRIALS trial_result · 2009-11-13Clinical Trial Update: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) [Phase 3]
Phase 3 trial of rilonacept for Cryopyrin-associated periodic syndromes (CAPS) completed with results posted in 2009.
-
FDA approval · 2009-06-17FDA Approved: ILARIS — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved ILARIS (canakinumab) under the original application for treatment of cryopyrin-associated periodic syndromes, including fam…
-
FDA approval · 2008-02-27FDA Approved: ARCALYST — Original Application (Kiniksa Pharmaceuticals (UK), Ltd.)
FDA approved ARCALYST (rilonacept) from its original Biologics License Application for the treatment of cryopyrin-associated periodic syndro…